Comparisons between semaglutide and tirzepatide often begin and end with a percentage. A more useful comparison starts with the treatment goal, the people studied, and the evidence behind each option. This guide offers a way to organize those questions without turning them into a personal prescription.
Understand the basic distinction
Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at both GIP and GLP-1 receptors. NIDDK’s overview places these medicines within a broader approach to treating overweight and obesity, including lifestyle support and assessment of medical suitability.
The number of receptor targets is not a score. The clinical evidence still has to show what the treatment achieves, for whom, and at what cost in adverse effects and treatment burden.
Sources: NIH / NIDDK
Give direct comparisons their proper scope
The SURMOUNT-5 trial directly compared tirzepatide with semaglutide in adults with obesity without diabetes. Published in May 2025, it found greater reductions in body weight and waist circumference with tirzepatide at 72 weeks.
The useful lesson is not that every person should switch. It is that a direct comparison supplies evidence for a particular population and regimen. The population, dose escalation, follow-up, and tolerability remain part of the finding.
Sources: New England Journal of Medicine — original trial
Compare the outcome you actually care about
Weight change, glucose control, quality of life, and clinical events are different outcomes. Identify which one your question concerns before choosing a paper. A favourable result for one endpoint should not be silently expanded into a claim about all of them.
If you are comparing summaries, make a simple table with columns for population, comparator, duration, primary endpoint, and safety findings. Leave a cell blank when the source does not provide it; a visible gap is better than an invented answer.
Include the practical questions
A treatment plan has to work outside a trial. Bring questions about side effects, other medicines, follow-up, affordability, and the intended duration of treatment to the prescribing clinician. NIDDK emphasizes working with a health professional to choose a medication that fits a person’s health history.
If treatment changes are being considered, ask what problem the change is meant to solve and how success will be evaluated. Do not convert a relative advantage in a trial into an automatic personal recommendation.
Sources: NIH / NIDDK
Read combination headlines with extra care
A new combination may be compared with placebo, with one component, or with an active medicine at a specified dose. Those designs answer different questions. Our CagriSema news report illustrates why the comparator dose belongs beside the result.
Keep the branded formulation and indication visible too. A molecular name alone is not enough to identify the exact product, route, or approved use involved in a medical decision.
Conclusion
A useful comparison combines the relevant trial with the individual treatment question. The headline number matters, but it cannot carry the decision on its own.